Are you Dr. Marks?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 56 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
800 Howard Ave
Yale Physicians Bldg
New Haven, CT 06519Phone+1 203-785-2140Fax+1 203-785-6414
Summary
- Dr. Peter Marks, MD is a hematologist in New Haven, Connecticut. He is currently licensed to practice medicine in Connecticut, New Jersey, and Massachusetts. He is an Associate Professor of Medicine at Yale University.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1993 - 1996- Brigham and Women's HospitalResidency, Internal Medicine, 1991 - 1993
New York University School of MedicineClass of 1991
Certifications & Licensure
CT State Medical License 2006 - 2025
MA State Medical License 1992 - 2025
NJ State Medical License 2004 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow (FACP) American College of Physicians, 2011
Publications & Presentations
PubMed
- 504 citationsA phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.Maria Domenica Cappellini, Alan R. Cohen, Antonio Piga, Mohamed Bejaoui, Silverio Perrotta
Blood. 2006-05-01 - 103 citationsA phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndromeMark Kirschbaum, Ivana Gojo, Stuart L. Goldberg, Christopher Bredeson, Lisa Kujawski
British Journal of Haematology. 2014-10-01 - 10 citationsASH Research Collaborative: A Real-World Data Infrastructure to Support Real-World Evidence Development and Learning Healthcare Systems in Hematology.William A. Wood, Peter W. Marks, Robert M. Plovnick, Kathleen Hewitt, Donna Neuberg
Blood Advances. 2021-10-21
Press Mentions
FDA Panel OKs New COVID Vaccine for FallJune 14th, 2024- $3.5M Gene Therapy for Hemophilia Gets FDA ApprovalNovember 22nd, 2022
- FDA Approves First Gene Therapy for Hemophilia BNovember 22nd, 2022
- Join now to see all
Professional Memberships
- Fellow
